David Harlan to Kidney Transplantation
This is a "connection" page, showing publications David Harlan has written about Kidney Transplantation.
Connection Strength
0.857
-
Kirk AD, Tadaki DK, Celniker A, Batty DS, Berning JD, Colonna JO, Cruzata F, Elster EA, Gray GS, Kampen RL, Patterson NB, Szklut P, Swanson J, Xu H, Harlan DM. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation. 2001 Aug 15; 72(3):377-84.
Score: 0.159
-
Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999 Jun; 5(6):686-93.
Score: 0.136
-
Khan MH, Harlan DM. Counterpoint: clinical islet transplantation: not ready for prime time. Diabetes Care. 2009 Aug; 32(8):1570-4.
Score: 0.069
-
Liu EH, Digon BJ, Hirshberg B, Chang R, Wood BJ, Neeman Z, Kam A, Wesley RA, Polly SM, Hofmann RM, Rother KI, Harlan DM. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia. 2009 Jul; 52(7):1369-80.
Score: 0.068
-
Ferrant JL, Benjamin CD, Cutler AH, Kalled SL, Hsu YM, Garber EA, Hess DM, Shapiro RI, Kenyon NS, Harlan DM, Kirk AD, Burkly LC, Taylor FR. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol. 2004 Nov; 16(11):1583-94.
Score: 0.049
-
Xu H, Elster EA, Blair PJ, Burkly LC, Tadaki DK, Harlan DM, Kirk AD. Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. Am J Transplant. 2003 Nov; 3(11):1350-4.
Score: 0.046
-
Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003 Jul 15; 76(1):120-9.
Score: 0.045
-
Montgomery SP, Xu H, Tadaki DK, Celniker A, Burkly LC, Berning JD, Cruzata F, Elster EA, Gray G, Kampen RL, Swanson SJ, Harlan DM, Kirk AD. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 2002 Nov 27; 74(10):1365-9.
Score: 0.043
-
Swanson SJ, Hale DA, Mannon RB, Kleiner DE, Cendales LC, Chamberlain CE, Polly SM, Harlan DM, Kirk AD. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet. 2002 Nov 23; 360(9346):1662-4.
Score: 0.043
-
Xu H, Tadaki DK, Elster EA, Burkly LC, Berning JD, Cruzata F, Kampen RL, Montgomery SP, Patterson NB, Harlan DM, Kirk AD. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation. 2002 Oct 15; 74(7):940-3.
Score: 0.043
-
Montgomery SP, Mog SR, Xu H, Tadaki DK, Hirshberg B, Berning JD, Leconte J, Harlan DM, Hale D, Kirk AD. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant. 2002 Apr; 2(4):381-5.
Score: 0.041
-
Xu H, Elster E, Batty D, Berning J, Burkly L, Kampen R, Swanson S, Tadaki D, Harlan D, Kirk A. Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. Transplant Proc. 2001 Feb-Mar; 33(1-2):223-4.
Score: 0.038
-
Knechtle SJ, Kirk AD, Fechner JH, Hong X, Dong Y, Hamawy MM, Harlan DM. Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. Transplant Proc. 1999 May; 31(3B Suppl):27S-28S.
Score: 0.034
-
Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997 Aug 05; 94(16):8789-94.
Score: 0.030
-
Montgomery SP, Hale DA, Hirshberg B, Harlan DM, Kirk AD. Preclinical evaluation of tolerance induction protocols and islet transplantation in non-human primates. Immunol Rev. 2001 Oct; 183:214-22.
Score: 0.010